Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

679
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
679
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

1.4K
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.5K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

786
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
786
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.9K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.9K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

597
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
597

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retraction notice for "MicroRNA-133b-5p Is Involved in Cardioprotection of Morphine Preconditioning in Rat Cardiomyocytes by Targeting Fas" [Canadian Journal of Cardiology, Volume 32, Issue 8, August 2016, Pages 996-1007. doi:10.1016/j.cjca.2015.10.019].

The Canadian journal of cardiology·2026
Same author

Ciprofol pharmacology and dosing in various populations.

Expert opinion on pharmacotherapy·2025
Same author

Total intravenous anaesthesia in emergency surgery: a narrative review.

Anaesthesia·2025
Same author

Single-Syringe Total Intravenous Anesthesia: Dosing Concerns.

Anesthesia and analgesia·2025
Same author

Remimazolam - drug evaluations: expert opinion on pharmacotherapy.

Expert opinion on pharmacotherapy·2025
Same author

Expanding the role of intranasal dexmedetomidine in peri-operative care.

Anaesthesia·2025

Related Experiment Video

Updated: Apr 9, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.8K

New therapy in cardioprotection.

Ka Ying Chow1, Sophie E Liu, Michael G Irwin

  • 1aQueen Mary Hospital, Hong Kong bHong Kong University, China.

Current Opinion in Anaesthesiology
|June 19, 2015
PubMed
Summary
This summary is machine-generated.

Cardioprotective interventions like statins and volatile anesthetics benefit patients undergoing major surgery. Beta blockers and aspirin continuation require careful perioperative management to balance risks and benefits.

More Related Videos

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

9.0K
Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.8K

Related Experiment Videos

Last Updated: Apr 9, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.8K
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

9.0K
Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.8K

Area of Science:

  • Anesthesiology
  • Cardiology
  • Perioperative Medicine

Background:

  • Increasing prevalence of cardiovascular comorbidities in surgical patients.
  • Myocardial injury affects 8% of non-cardiac surgery patients over 45, correlating with adverse outcomes.
  • Need for effective cardioprotective strategies in major surgery.

Purpose of the Study:

  • Evaluate cardioprotective interventions for patients with cardiovascular comorbidities undergoing non-cardiac surgery.
  • Identify agents and strategies that mitigate perioperative myocardial injury.
  • Provide evidence-based recommendations for managing cardiac medications during surgery.

Main Methods:

  • Review of current evidence on perioperative cardioprotective agents.
  • Analysis of the impact of specific anesthetic agents (volatile agents, propofol) on myocardial injury.
  • Assessment of the role of beta blockers, alpha 2 agonists, aspirin, and nitrous oxide in perioperative cardiac risk.

Main Results:

  • Statins, volatile anesthetics, and propofol demonstrate cardioprotective effects.
  • Beta blockers reduce myocardial injury but can cause hypotension; alpha 2 agonists require careful management to avoid cardiac injury.
  • Perioperative aspirin continuation may increase bleeding risk; nitrous oxide appears safe regarding myocardial injury.

Conclusions:

  • Continue statins and beta blockers perioperatively for patients already taking them.
  • Titrate beta blocker dosage to heart rate and blood pressure if initiated perioperatively.
  • Individualize aspirin continuation decisions based on patient and surgical risk factors.